WhiteOak Capital Pharma and Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV: ₹ 10.21 as on 02-05-2024
About the Fund
WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 6 February, 2024. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has ₹109 Cr worth of assets under management (AUM) as on Mar 2024 and is less than category average.
- The fund has an expense ratio 0.6.
Fund Performance
386 people have invested ₹ 19.9L in WhiteOak Capital Pharma and Healthcare Fund Direct Growth in the last three months
Overview
 | 0.6% |
 Benchmark | S&P BSE Healthcare PR |
 | ₹109 Cr |
 | 6 February, 2024 |
 | ₹100/₹100 |
 Exit Load | 1% |
 | No Lock-in |
 TurnOver | 0% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Distribution as on (31-Mar-24)
Size breakup
Small cap
45.6%
Large cap
35.8%
Mid cap
12.8%
Sector Allocation
Health
97.4%
Basic Materials
2.6%
Top Holdings of WhiteOak Capital Pharma and Healthcare Fund Direct Growth as on (30-Apr-24)
Equity Holdings28
Debt Holdings2
Gainers & Losers Returns for the month of Mar
Top Growth Drivers | 1M Return |
|---|---|
 Neuland Laboratories Ltd | 17.3% |
 J B Chemicals & Pharmaceuticals Ltd | 13.8% |
Global Health Ltd | 8.5% |
Peer Analysis
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered returns of 2.01% since inception (06nd Feb 2024)
Fund Allocations
This fund has an allocation of 97.04% in Equity, 0% in Debt and 2.96% in Cash related instruments
AUM size ₹109 Cr
This fund has AUM of ₹109 Cr which is less than its category average of ₹ 1652 Cr
Expense Ratio 0.6%
This fund has an expense ratio of 0.6% which is less than its category average expense ratio of 1.45%
Frequently Asked Questions
The current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is ₹10.21 as on 02-May-2024.
Existing (Absolute + CAGR) as on 02-May-2024.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 2.16% | 2.16% |
6 Month Returns | 0% | 0% |
1 Year Returns | 0% | 0% |
3 Years Returns | 0% | 0% |
5 Years Returns | 0% | 0% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.6% as on April 2024
₹109 Cr as on April 2024
Sun Pharmaceuticals Industries Ltd(14.1%), Cipla Ltd(9.52%), Torrent Pharmaceuticals Ltd(6.94%), Zydus Lifesciences Ltd(6.07%), Mankind Pharma Ltd(5.23%) as on April 2024
The alpha ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on April 2024
The alpha for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on April 2024
The Beta for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on April 2024
The sharpe ratio for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on April 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is 1%